Raf激酶抑制蛋白与恶性肿瘤

Raf kinase inhibitor protein and malignant tumor

Raf激酶抑制蛋白（RKIP）是磷脂酰乙醇胺结合蛋白家族的成员。RKIP在Raf、核转录因子-κB（NF-κB）及G蛋白偶联受体（GPCR）等蛋白激酶信号传导通路中起重要调节作用。RKIP参与神经发育、心脏功能、精子发生、细胞迁移及巨噬细胞分化，同时还具有丝氨酸蛋白酶活性。近年来众多资料表明，RKIP在多种恶性肿瘤中表达减弱或丢失，其在恶性肿瘤中作用机制已经成为研究的热点，该类研究将为今后肿瘤治疗提供新的靶点。

Raf kinase inhibitor protein （RKIP） is a member of the phosphatidylethanolamine- binding protein family. RKIP blocks Raf-induced phosphorylation of mitogen-activated protein kinase kinases （MEK）. In addition to its modulation of Raf signaling, RKIP modulates both G-protein signaling and NF-kB activity. RKIP is involved in neural development, cardiac function, spermatogenesis, cell migration and macrophage dif- ferentiation and appears to have serine protease activity. RKIP levels are found to be reduced or lost in many malignant tumors. The more that is defined about RKIP and its role in malignant tumor may help identify RKIP or proteins downstream of RKIP as new targets for cancer treatment.